Development of stabilised mixtures of fluorescentally labelled antibodies in a single test pack for flow cytometry (Q12098): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Removed claim: financed by (P890): Directorate-General for Regional and Urban Policy (Q8361), Removing unnecessary financed by statement)
(‎Changed an Item: Change because item Q214255 was merged with Q4859)
Property / contained in NUTSProperty / contained in NUTS

Revision as of 16:21, 27 December 2020

Project Q12098 in Czech Republic
Language Label Description Also known as
English
Development of stabilised mixtures of fluorescentally labelled antibodies in a single test pack for flow cytometry
Project Q12098 in Czech Republic

    Statements

    country
    Czechia
    0 references
    EU contribution
    11,165,000.0 Czech koruna
    0 references
    446,600.0 Euro
    exchange rate to Euro
    0.04 Euro
    point in time
    10 January 2020
    0 references
    budget
    22,330,000.0 Czech koruna
    0 references
    893,200.0 Euro
    exchange rate to Euro
    0.04 Euro
    point in time
    10 January 2020
    0 references
    co-financing rate
    50 percent
    0 references
    expected end time
    31 December 2020
    0 references
    beneficiary name (string)
    EXBIO Praha, a.s.
    0 references
    beneficiary
    Q197450
    0 references
    coordinate location

    49°59'0.49"N, 14°30'9.11"E
    0 references
    postal code
    25250
    0 references
    summary
    Cílem projektu je zvýšení kapacit vlastního VaV společnosti EXBIO Praha, a.s. v oblasti stabilizovaných směsí fluorescenčně značených protilátek v jednotestovém balení pro průtokovou cytometrii. Rozšíření VIK posílí postavení společnosti na světovém obchodu s monoklonálními protilátkami, jejich deriváty a diagnostickými soupravami pro klinickou diagnostiku ve zdravotnictví a umožní další rozšíření a diversifikaci produktů především do zdravotnické diagnostiky. a. (Czech)
    0 references
    The aim of the project is to increase the R & D capacity of Exbio Praha, a.s. in the area of stabilised mixtures of fluorescence-labelled antibodies in a single-test packaging for flow cytometry. The expansion of VIK will strengthen the company’s position in the world trade in monoclonal antibodies, their derivatives and diagnostic kits for clinical diagnosis in health care and will allow further expansion and diversification of products mainly into medical diagnostics. a. (English)
    point in time
    22 October 2020
    0 references

    Identifiers

    Czech Kohesio ID
    CZ.01.1.02/0.0/0.0/17_165/0015522
    0 references
     
    Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q12098&oldid=9201431"